Eli Lilly & Co. (LLY) Tops Q1 EPS by 9c; Reaffirms FY13 Outlook

Eli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $1.14, $0.09 better than the analyst estimate of $1.05. Revenue for the quarter came in at $5.6 billion versus the consensus estimate of $5.66 billion.

Eli Lilly & Co. reaffirmed FY2013 guidance.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Imunon (IMNN) Tops Q2 EPS by 39c
• Coya Therapeutics, Inc. (COYA) Tops Q2 EPS by 42c
• KeyBanc on Rocket Lab USA (RKLB): 'Iridium Sparks the Next Growth Phase'